What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
复制标题
DOI：
10.1182/blood-2008-01-130237
复制
发表时间：
2008-09-01
期刊：
影响因子：
20.3
通讯作者：
Nachman, James
中科院分区：
文献类型：
--
作者：
Stock, Wendy;La, Mei;Nachman, James
我们对1988年至2001年在儿童癌症组（CCG）或癌症和白血病组B（CALGB）接受连续试验治疗的321例16 - 20岁新诊断急性淋巴细胞白血病（ALL）青少年和青年（AYAs）的临床特征、计划治疗、完全缓解（CR）率和结局进行了回顾性比较。CALGB和CCG AYA的CR率相同，均为90%。CCG AYA的7年无事件生存率（EFS）为63%，总生存率（OS）为67%，而CALGB AYA的7年EFS仅为34%（P
We performed a retrospective comparison of presenting features, planned treatment, complete remission (CR) rate, and outcome of 321 adolescents and young adults (AYAs) ages 16 to 20 years with newly diagnosed acute lymphoblastic leukemia (ALL) who were treated on consecutive trials in either the Children's Cancer Group (CCG) or the Cancer and Leukemia Group B (CALGB) from 1988 to 2001. CR rates were identical, 90% for both CALGB and CCG AYAs. CCG AYAs had a 63% event-free survival (EFS) and 67% overall survival (OS) at 7 years in contrast to the CALGB AYAs, in which 7-year EFS was only 34% (P